These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33361600)

  • 1. Cingulate Island Sign in Single Photon Emission Computed Tomography: Clinical Biomarker Correlations in Lewy Body Disease and Alzheimer's Disease.
    Futamura A; Hieda S; Mori Y; Sugimoto A; Kasai H; Kuroda T; Yano S; Kasuga K; Murakami H; Ikeuchi T; Ono K
    J Alzheimers Dis; 2021; 79(3):1003-1008. PubMed ID: 33361600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
    Geng C; Tan L; Chen C
    Brain Res; 2024 Jun; 1833():148881. PubMed ID: 38519009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of brain perfusion patterns in dementia with Lewy bodies patients with or without cingulate island sign.
    Ishibashi M; Kimura N; Sumi K; Aso Y; Matsubara E
    Geriatr Gerontol Int; 2019 Mar; 19(3):197-202. PubMed ID: 30548751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies.
    Iizuka T; Kameyama M
    Ann Nucl Med; 2016 Jul; 30(6):421-9. PubMed ID: 27098829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.
    Vijayaraghavan S; Maetzler W; Reimold M; Lithner CU; Liepelt-Scarfone I; Berg D; Darreh-Shori T
    Alzheimers Dement; 2014 Sep; 10(5):530-540.e1. PubMed ID: 23978325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cingulate Island Sign on FDG-PET vs. IMP-SPECT to Assess Mild Cognitive Impairment in Alzheimer's Disease vs. Dementia with Lewy Bodies.
    Chiba Y; Fujishiro H; Iseki E; Kasanuki K; Sato K
    J Neuroimaging; 2019 Nov; 29(6):712-720. PubMed ID: 31199036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased perfusion of the posterior cingulate gyri shown by a cingulate island score is a possible marker of vulnerability to behavioural and psychological symptoms of Alzheimer's disease: a pilot study.
    Yasuno F; Matsuoka K; Miyasaka T; Takahashi M; Kitamura S; Yoshikawa H; Hattori H; Kichikawa K; Kishimoto T
    Psychogeriatrics; 2019 Mar; 19(2):165-170. PubMed ID: 30276946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
    Schaeffer MJ; Callahan BL;
    J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study protocol on Alzheimer's disease and related disorders: focus on clinical and imaging predictive markers in co-existing lesions.
    Boublay N; Fédérico D; Pesce A; Verny M; Blanc F; Paccalin M; Desmidt T; Grosmaître P; Moreaud O; Relland S; Bravant E; Bouet R; Krolak-Salmon P
    BMC Geriatr; 2018 Nov; 18(1):280. PubMed ID: 30428832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic dysfunction, neurodegeneration, and amyloid-beta pathology in neurodegenerative diseases.
    Petrova T; Orellana C; Jelic V; Oeksengaard AR; Snaedal J; Høgh P; Andersen BB; Naik M; Engedal K; Wahlund LO; Ferreira D
    Psychiatry Res Neuroimaging; 2020 Aug; 302():111099. PubMed ID: 32505903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.